Which #microcap company should I create the next thread about? Follow the thread to vote!

Please read their screener.in pages and company websites before deciding. I'll also add a few lines for those who don't want to do that.
1. RACL geartech
A precision gear manufacturer (Soma Comstar rings a bell?) supplying to BMW, kubota, Yamaha, KTM. Sticky client relationship built over years. Aiming to grow topline from 180cr to 500cr in next 4 years. Industry leading margins of 15-20%. EV unlikely to disrupt.
Co is also undertaking 50cr capex which is likely to commence soon.
High precision gears are requirement for EV so that noise levels are low since RPM and torque are higher. RACL could benefit on margins whenever clients move to EV.
2. Kilpest
Leading Biotech firm that makes diagnostics kits. Their non covid diagnostics biz is and was growing at 30-40% pre covid. If we remove the cash in balance sheet and look purely at the non covid diagnostics biz it's available at around 10-15 pe.
Market is unable to see the non-covid business. Co doing many actions for minority investors like renaming to bring out focus on biotech subsidiary, potential acquisition or share buyback worth 100-120cr. Their covid test kit is only Indian one approved by USFDA. Interesting.
Only one of 5 companies with Saliva based Covid kit approved by USFDA under EUA. Opportunity size is huge Number of molecular diagnostics labs went from 400 pre covid to 2600 now. Co also working on NGS (Next Gen Sequencing) kits:
3. Rajshree Polypack
Co makes plastic packaging for marquee global FMCG clients, who are very stringent on quality checks & it takes many years to enter these supply chains. They haven’t lost any major customer in last 10 years. Makes kinderjoy packaging for China & India
Company is ahead of the curve on innovation. They are ready with biodegradable packaging (made from corn) & can supply when clients want to move. Other exciting upcoming products: Recyclable packaging, barrier packaging (longer shelf life for food), tubes packaging (cosmetics)
4. Sasta Sundar Ventures
Only listed E-pharmacy right now. Close to break even. Interesting hybrid phigital business model: HealthBuddy stores establish human connection with clients, clients order in store or on app. Industry growing at 40-060% CAGR. Huge opportunity size.
Competitors like pharmeasy and 1mg rely heavily on Digital ads. Once ministry of health e-pharmacy rules are implemented, would level playing field for SastaSundar (SS). Pic is from a dated 2018 presentation. Timelines would change, but shows management's ambition
Which one of these 4 companies should I make next thread on?
Please retweet the first tweet for maximum reach. 🙏

All of these are microcaps. Please do your own due diligence before investing. I am invested in all 4 and positively biased.
People that don't follow might miss the next thread. Baki dekh lo. 🤣

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Sahil Sharma

Sahil Sharma Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sahil_vi

20 Jun
what better way to start sunday than a #kilpest thread: a classic peter lynch pick & shovel investment for the diagnostics sector. If you like the thread, please retweet this tweet to help educate max investors. 🙏🙏
Before I dive into Kilpest, some words on microcap investing. Everyone **needs** to be aware of what they are signing up for.
Two interviews from @varinder_bansal sir’s Omkara capital with very successful microcap investors (one with @iancassel sir: ...
Read 77 tweets
12 Jun
#neulandlab 🌋🌋 read on to understand this company and its story of transformation. On twitter, 🌋 has become synonymous with neuland, and this is how i will use it throughout the thread. If you like the thread, plz retweet & help fellow investors learn
Starting with a simple primer on the Pharma industry. They make medicines for all of us. The part of the medicine which gives it its potency against the ailment it cures is called API: Active Pharmaceutical Ingredient:
en.wikipedia.org/wiki/Active_in…
(here is a reference few people will get, but have to make it since I love it :D):
If Guardians of the globe (imagecomics.fandom.com/wiki/Guardians…) were a medicine, Omniman (imagecomics.fandom.com/wiki/Nolan_Gra…) is the API.
Read 56 tweets
30 May
#idfcfirstbank is my largest and oldest investment. Thought of creating a thread to explain the business. If you like the thread, please spread the knowledge, retweet. Buckle up, because this is going to be a long one. :D
Quick summary of what a bank does. This enables me to establish a framework under which the analysis of the bank will become very structured.
Money is its raw material.
Bank takes customer deposits, raises money via borrowings (can issue its own bonds, takes loans from other banks etc). This is the input for the bank. Since the bank is liable to pay interest on it, it is also known as liabilities.
Read 66 tweets
27 May
#garware hi-tech films Q4 concall happened today. My key takeaways. If you find the thread useful, please RT so it can be benefit maximum investors.
1. Gross Margins dropped by 5% compared to Q3.
In b/w lines: RM prices increased 5%.
However they pass on all price increases to customers with some lag. Will be able to pass on prices July onwards. Should see increase in gross margins July onwards. QoQ margin volatility is bound to be there when RM prices cannot be immediately passed on.
Volatility in stock price is not risk it is an opportunity to buy for an informed investor. Did the value of company change by 10% intraday? No.
Read 10 tweets
27 May
What better way to start a Thursday morning than with key takeaways from #Laurus Q4 results.
1. Aiming to do 1B$ in revenue in FY23 maintain 30% EBITDA margins.
In b/w lines: In b/w lines: Will diversify API & formulation division and grow the anti-diabetic, oncology API and formulations division.
Laurus also increased capex guidance from 1100 cr in last Q to 1500cr-1700cr over FY22 and FY23. Not all of capex done in FY23 would contribute to 1B$ sales target.
Read 16 tweets
25 May
In this context, recent talk by prof @Sanjay__Bakshi becomes very interesting:


Amazing talk 🙏🙏 I have requested even my non investor friends & family to watch. The opposite of a good idea, can also be a good idea. 😁
Teaches us importance of humility
To clarify the talk happened in November 2020 but was uploaded by @CFASocietyIndia yesterday.
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(